Cargando…

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination

Detalles Bibliográficos
Autores principales:	Liu, Yuag-Meng, Lee, Yu-Lin, Liu, Chun-Eng, Chen, Yi-Chun, Tien, Ni, Su, Wen-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483497/ https://www.ncbi.nlm.nih.gov/pubmed/36109464 http://dx.doi.org/10.1007/s15010-022-01922-8

Ejemplares similares

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
por: Routhu, Nanda Kishore, et al.
Publicado: (2023)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273
por: Hernández, Jesús, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
por: Williams, Curtis B., et al.
Publicado: (2021)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
por: Lopes de Assis, Felipe, et al.
Publicado: (2023)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
por: Bellusci, Lorenza, et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2020)

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
por: Oronsky, Bryan, et al.
Publicado: (2021)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
por: Mencarelli, Lucrezia, et al.
Publicado: (2023)

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination
por: Rujkorakarn, P., et al.
Publicado: (2023)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021)

A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine
por: Murvelashvili, Natia, et al.
Publicado: (2021)

mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2021)

Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine
por: Iftikhar, Haris, et al.
Publicado: (2021)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
por: Channa, Leelakrishna, et al.
Publicado: (2021)

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
por: Girard, Bethany, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
por: Holzworth, Amy, et al.
Publicado: (2021)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Radiation recall phenomenon after administration of the mRNA-1273 SARS-CoV-2 vaccine
por: Ishikawa, Yojiro, et al.
Publicado: (2022)

Acute Myocarditis in a Patient Following mRNA-1273 SARS-CoV-2 Vaccination
por: Kawakami, Toshinaru, et al.
Publicado: (2022)

Parsonage Turner Syndrome Following Vaccination With mRNA-1273 SARS-CoV-2 Vaccine
por: Bernheimer, James H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ieg8u4uirl2lphtm9jf47qbrn0